Skip to main content

Table 2 Clinical course of patients with pulmonary metastases from PDAC who received pulmonary resection

From: Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study

Case Age/Sex PDAC surgery pStage Adjuvant chemotherapy RFS (Months) PM location (tumour number) Neoadjuvant chemotherapy PM surgery 2nd adjuvant chemotherapy RFS (PM surgery) (months) 2nd recurrence site 2nd recurrence treatment OS (Months)
1 72M PPPD + PVR 2B - 36 Left upper lobe (1)
Left lower lobe (1)
Partial resection 98 132 (Alive)
2 66F SSPPD 3 S-1 47 Right upper lobe (1)
Right lower lobe (2)
Partial resection 13 60 (Alive)
3 68M SSPPD + PVR 3 S-1 24 Right upper lobe (1)
Left upper lobe (1)
Partial resection 3 Right pulmonary
metastases
GEM + nab-PTX
 → FFX
55 (Alive)
4 70M SSPPD + PVR 2B S-1 13 Left lower lobe (2) Partial resection 3 Right pulmonary
metastases
GEM + nab-PTX 32 (Alive)
5 71M DP 3 S-1 31 Right upper lobe (1)
Right Lower lobe (1)
GEM + nab-PTX Partial resection GEM + nab-PTX
 → GEM
9 53 (Alive)
6 80M DP 1A S-1 36 Right upper lobe (1)
Left upper lobe (1)
GEM + nab-PTX Partial resection 3 59 (Alive)
  1. PPPD pylorus-preserving pancreaticoduodenectomy, SSPPD subtotal stomach preserving pancreaticoduodenectomy, DP distal pancreatectomy, PVR portal vein resection, PM pulmonary metastasis, GEM gemcitabine, nab-PTX nab-paclitaxel, FFX FOLFIRINOX, RFS recurrence-free survival